MX9503885A - Skin problems treatment with ii-cis-retinoic acid. - Google Patents

Skin problems treatment with ii-cis-retinoic acid.

Info

Publication number
MX9503885A
MX9503885A MX9503885A MX9503885A MX9503885A MX 9503885 A MX9503885 A MX 9503885A MX 9503885 A MX9503885 A MX 9503885A MX 9503885 A MX9503885 A MX 9503885A MX 9503885 A MX9503885 A MX 9503885A
Authority
MX
Mexico
Prior art keywords
cis
skin
psoriasis
retinoic acid
abnormal
Prior art date
Application number
MX9503885A
Other languages
Spanish (es)
Inventor
Mark S Braiman
Original Assignee
Rich Robins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rich Robins filed Critical Rich Robins
Priority to MX9503885A priority Critical patent/MX9503885A/en
Priority to EP96915529A priority patent/EP0824348B1/en
Priority to PCT/US1996/006359 priority patent/WO1996034601A1/en
Priority to AU57285/96A priority patent/AU5728596A/en
Priority to AT96915529T priority patent/ATE223714T1/en
Priority to DE69623612T priority patent/DE69623612T2/en
Publication of MX9503885A publication Critical patent/MX9503885A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The ??present invention discloses a distinctive, uic acid, or neotretinoin), which is usefulfor the treatment of abnormal cell differentiation or abnormal cell hyperproliferation conditions, such as psoriasis. The addition of said compound (II-Cis-Retinoic acid) to a non-irritating vehicle, is useful as a cosmetic that promotes a healthier and rejuvenated look to abnormal skin. A new method to synthesize said isomer allows to therapeutically compare it with the more commonly available isomers: 13-Cis isomer and all Trans isomer. As shown in the inventor's skin, who suffers psoriasis condition, the topical application of II-Cis-Retinoic acid to skin is much more advantageous for reducing symptoms, and substantially reduces the resulting side effects, as compared with the topical treatment using other isomers. A single application of a neotretinoin emulsion (0.001 percentby weight) to psoriasis injuries, results in a substantial improvement to the symptoms (itching, imbrication, being bleeding, look abnormal) within the following 48 hours. A continuous application results in a total remission. No irritation, erythema, nor other side effects are observed.
MX9503885A 1995-05-05 1995-09-11 Skin problems treatment with ii-cis-retinoic acid. MX9503885A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX9503885A MX9503885A (en) 1995-09-11 1995-09-11 Skin problems treatment with ii-cis-retinoic acid.
EP96915529A EP0824348B1 (en) 1995-05-05 1996-05-06 Treatment of psoriasis with 11-cis-retinoic acid
PCT/US1996/006359 WO1996034601A1 (en) 1995-05-05 1996-05-06 Treatment of psoriasis with 11-cis-retinoic acid
AU57285/96A AU5728596A (en) 1995-05-05 1996-05-06 Treatment of psoriasis with 11-cis-retinoic acid
AT96915529T ATE223714T1 (en) 1995-05-05 1996-05-06 TREATMENT OF PSORIASIS WITH 11-CIS-RETIN ACID
DE69623612T DE69623612T2 (en) 1995-05-05 1996-05-06 TREATMENT OF PSORIASIS WITH 11-CIS RETINIC ACID

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX9503885A MX9503885A (en) 1995-09-11 1995-09-11 Skin problems treatment with ii-cis-retinoic acid.

Publications (1)

Publication Number Publication Date
MX9503885A true MX9503885A (en) 1997-03-29

Family

ID=38819542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9503885A MX9503885A (en) 1995-05-05 1995-09-11 Skin problems treatment with ii-cis-retinoic acid.

Country Status (1)

Country Link
MX (1) MX9503885A (en)

Similar Documents

Publication Publication Date Title
DE69509891T2 (en) INHIBITION OF HAIR GROWTH
DE69505651T2 (en) INHIBIT HAIR GROWTH
EP0167062B1 (en) Topical composition
DE69128034T2 (en) ENZYMATIC CHANGE IN HAIR GROWTH
US5951989A (en) Method for the treatment of dry skin
DE69304292T2 (en) Tetracyclines including non-antimicrobial, chemically modified tetracyclines inhibiting excessive collagen cross-linking in diabetes
EP0863740B1 (en) Reduction of hair growth
US4997853A (en) Method and compositions utilizing capsaicin as an external analgesic
HAMILTON Effect of castration in adolescent and young adult males upon further changes in the proportions of bare and hairy scalp
US4569935A (en) Topical treatment of psoriasis with imidazole antibiotics
CA2308006A1 (en) Topical compositions for regulating the oily/shiny appearance of skin
DE69726001T2 (en) REDUCTION OF HAIR GROWTH
DE69502130T2 (en) Polyene derivatives, pharmaceutical and cosmetic compositions containing them and their use
AU675918B2 (en) Treatment of acne or of pseudofolliculitis barbae
US20040102358A1 (en) Composition for treating skin conditions
DE3750934T2 (en) Treatment of non-acne inflammatory and infectious skin diseases.
US4942162A (en) Topical treatment of seborrheic dermatitis with ketoconazole
DE69621076T2 (en) Use of specific RXR receptor ligands
WO1992012699A1 (en) Cosmetic or pharmaceutical compositions for improving hair quality and promoting hair growth
CA2002859A1 (en) Method of treating epithelial disorders
AU758594B2 (en) Method and composition for treating acne
Weinstein Tazarotene gel: efficacy and safety in plaque psoriasis
AU6333794A (en) Retinoid composition
DE69934410T2 (en) TREATMENT OF ACNE AND LIGHT-ORIGINAL AGING BY SHORT-TERM TREATMENT WITH TOPICAL RETINOIDS
EP1050298A3 (en) Composition for treating and/or ameliorating the diseases of dandruff, seborrheic dermatitis, psoriasis and eczema and symptoms thereof

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees